Further, the quant system, as mentioned, there's likely no mispricing.

Source: https://seekingalpha.com/article/4607077-angiodynamics-angiovac-profit-headwinds-not-attractive?source=feed_all_articles

The company could be fairly valued at $317/share, indicating potential mispricing.

Source: https://seekingalpha.com/article/4611595-inspire-medical-systems-valuation-sentiment-fundamental-factors-call-for-rerating?source=feed_all_articles

This focus on paying a fair price for exposure to high quality companies has allowed the Index to provide risk mitigation in difficult markets and exploit mispricing in order to participate in the upside.

Source: https://seekingalpha.com/article/4614554-moat-delivers-quality-with-a-forward-looking-edge?source=feed_all_articles